Basis: unit costs and per-well/per-plate assumptions for Adalimumab (L929/TNF-α+ActD), Trastuzumab (BT-474), Rituximab (WIL2S/complement-CDC) and Bevacizumab (HUVEC/VEGF) are drawn from JB Scientific Quotation SO‑01182 (25‑Jul‑2026) and cross-checked against SAMI Annexures 10, 12, 18 & 19 (8-point dilution, triplicate standard/sample/controls, protocol-specific detection-reagent volumes). Custom assays use the same cost engine with a cell line selected from the JBS product catalogue — 843 living cell-line SKUs (17 direct-supplier lines from Cytion/Takara/Genscript plus 826 from Procell, whose cell-line listings the catalogue's auto-detected "Product Type" filter mislabels as "Consumable" — pulled here by SKU prefix instead) — and editable reagent economics.
Caveats: a few line items (human complement serum, gloves/gowns/parafilm, dilution blocks) aren't itemised in the quotation and use flagged Pakistan market-rate placeholders. Equipment depreciation is spread across an assumed annual plate throughput — adjust it in Advanced cost settings to your real order volume. GST is shown separately; confirm with finance whether a quoted rate should be inclusive or exclusive. Treat this as a planning and quoting model, not an audited cost account or a substitute for your own SOP sign-off.
Svar Life Science kits: the biologic dropdown now covers 42 biologics/drug names, merged and de-duplicated from the Svar RANKL/TNF-alpha/VEGF/G-CSF application notes (LABEL-DOC-0405, -0445, -0480, -0482, -0504, -0694) and the user-supplied "Svar Kits & Biologics Matrix" and "Svar Biologics QC Products" workbooks (Svar Claude List / DrugMap / Drug Selector sheets) — every one is a full selectable workflow (own reagents, protocol and cost breakdown), not a reference row. Svar's iLite® Assay Ready Cells are single-use (not sub-cultured), so every Svar route is costed 1 vial = 1 plate rather than amortized like the JBS/Cytion lines. Only three SKUs (BM4044 TNF-α family, BM4021 VEGF family, BM4052 RANKL) were confirmed live in the JBS catalogue on 20-Sep-2026 at a real landed PKR 1,300,000/vial; every other kit falls back to Svar's EUR list-price estimate — flagged on-screen either way. Six workflows (Adalimumab/Trastuzumab/Rituximab/Bevacizumab/Denosumab/G-CSF's TNF-α, VEGF, RANKL and G-CSF routes) follow Svar's own confirmed application-note protocols; every other Svar-kit workflow (CD20/CDC, IL-23, IL-6, insulin, complement pathways, etc.) follows a generic iLite®/WIESLAB® protocol pattern inferred from those confirmed notes, since Svar didn't supply a target-specific IFU for the rest — clearly flagged on each workflow's cost-notes banner. The remaining ~10 Svar kits with no clean 1:1 biologic (paired ADCC/ADCP target+effector lines, AAV packaging kits) are reference-only in the kit cross-reference table below.
Eurofins DiscoverX PathHunter® kits: a second kit-based route, alongside Svar, using β-galactosidase enzyme-fragment-complementation (EFC) rather than a luciferase reporter. Four biologic-relevant kits were found live in the JBS catalogue on 20-Sep-2026 (Adalimumab 93-0538B15-00131, Bevacizumab 93-0996Y1-00001, a generic RANK-IκB kit 93-0994C3 usable for Denosumab, and a generic CSF3R-JAK1 kit 93-0809C3 usable for G-CSF biologics) and are modelled as full selectable workflows at their real, landed kit prices. DiscoverX does not publish exact well volumes/timings for these specific kits online, so protocol figures follow the generic published PathHunter Bioassay pattern and are flagged for verification against each kit's own physical insert; the RANK-IκB and CSF3R-JAK1 kits also have unconfirmed plate-yield/pack-size figures (flagged on-screen) since they are generic pathway kits rather than biologic-branded bundles. Trastuzumab and Rituximab were checked directly against both Svar and the JBS/PathHunter catalogue and currently have no live kit-based route for either supplier. The remaining PathHunter/cAMP Hunter kits are reference-only in the kit cross-reference table below.